Literature DB >> 18019630

Receptor PET/CT imaging of neuroendocrine tumors.

R P Baum1, V Prasad, M Hommann, D Hörsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18019630     DOI： 10.1007/978-3-540-31203-1_18

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


× No keyword cloud information.
  17 in total

Review 1.  Neuroendocrine Pulmonary Tumors of Low, Intermediate and High Grade: Anatomopathological Diagnosis-Prognostic and Predictive Factors.

Authors:  José Manuel Cameselle-Teijeiro; José Antonio Mato Mato; Ovidio Fernández Calvo; Jesús García Mata
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

2.  A new automated NaCl based robust method for routine production of gallium-68 labeled peptides.

Authors:  Michael K Schultz; Dirk Mueller; Richard P Baum; G Leonard Watkins; Wouter A P Breeman
Journal:  Appl Radiat Isot       Date:  2012-08-31       Impact factor: 1.513

3.  Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.

Authors:  Aurora Sainz-Esteban; Vikas Prasad; Christiane Schuchardt; Carolin Zachert; José Manuel Carril; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-20       Impact factor: 9.236

4.  Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.

Authors:  Daniel Kaemmerer; Vikas Prasad; Wolfgang Daffner; Dieter Hörsch; Günter Klöppel; Merten Hommann; Richard P Baum
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

5.  68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.

Authors:  A Kroiss; D Putzer; C Decristoforo; C Uprimny; B Warwitz; B Nilica; M Gabriel; D Kendler; D Waitz; G Widmann; I J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-05       Impact factor: 9.236

6.  Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management.

Authors:  Hans Scherübl; Robert T Jensen; Guillaume Cadiot; Ulrich Stölzel; Günter Klöppel
Journal:  World J Gastrointest Endosc       Date:  2010-10-16

7.  Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors.

Authors:  Daniel Kaemmerer; Luisa Peter; Amelie Lupp; Stefan Schulz; Jörg Sänger; Richard Paul Baum; Vikas Prasad; Merten Hommann
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

8.  The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm.

Authors:  D Kaemmerer; N Posorski; F von Eggeling; G Ernst; D Hörsch; R P Baum; V Prasad; R Langer; I Esposito; G Klöppel; S Sehner; T Knösel; M Hommann
Journal:  Clin Exp Metastasis       Date:  2014-08-07       Impact factor: 5.150

9.  Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.

Authors:  Vikas Prasad; Valentina Ambrosini; Merten Hommann; Dieter Hoersch; Stefano Fanti; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

10.  Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.

Authors:  Vikas Prasad; Nikolaus Tiling; Timm Denecke; Winfried Brenner; Ursula Plöckinger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-13       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.